RxDoctor Payments Data

Brian Walter, DO

Neurology · Sugar Land, TXNPI 1114394798

Payments from drug & device makers

$11,493in general payments, 2019–2025

Across 557 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$1K
  • Neurocrine Biosciences, Inc.$891
  • Novartis$868
  • SK Life Science, Inc.$829
  • Pfizer$809
  • plus $4K from 39 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$11,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,493 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$153,570
Medicare patients
454
Services billed
3,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5045$215,437
Dimethyl Fumarate12$43,673
Nurtec OdtRimegepant Sulfate22$42,309
AptiomEslicarbazepine Acetate24$28,671
Memantine Hcl402$21,383
BriviactBrivaracetam11$17,564
UbrelvyUbrogepant14$16,849
Aimovig AutoinjectorErenumab-Aooe22$16,460
FycompaPerampanel12$13,827
Donepezil Hcl645$8,050
Gabapentin223$5,456
Rivastigmine32$5,059
Pregabalin114$4,012
Memantine Hcl ErMemantine Hcl35$3,519
Carbidopa-LevodopaCarbidopa/Levodopa90$3,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$809$257,74567 claims
UCB, Inc.Briviact$1,338$17,56411 claims
AbbVieUbrelvy$2,624$16,84914 claims
Eisai Inc.Fycompa$319$13,82712 claims
Almatica Pharma LLCSertraline Hcl$18$5014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →